NCT00343941View on ClinicalTrials.gov

Tucaresol As Add-On To HAART (Highly Active Antiretroviral Therapy) In Chronic HIV-1 Infected Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 30, 2004

Conditions
HIV Infection
Interventions
DRUG

Tucaresol tablets 25 mg

Trial Locations (7)

20127

GSK Investigational Site, Milan

20157

GSK Investigational Site, Milan

21052

GSK Investigational Site, Busto Arsizio (VA)

24128

GSK Investigational Site, Bergamo

35128

GSK Investigational Site, Padua

50126

GSK Investigational Site, Bagno A Ripoli (FI)

50139

GSK Investigational Site, Florence

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00343941 - Tucaresol As Add-On To HAART (Highly Active Antiretroviral Therapy) In Chronic HIV-1 Infected Adults | Biotech Hunter | Biotech Hunter